Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
To keep a close eye on the gap between doses delivered to states and doses delivered to arms, the Commonwealth Fund created a State and Federal Vaccine Rollout Tracker.
